Clinical trial
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic…
NCT00037011 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00037011 |
|---|---|
| Title | Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma |
| Official title | Phase I Study of Oral Beta-Glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients With Metastatic Neuroblastoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | beta-glucan, monoclonal antibody 3F8 |
| Start date | Nov 1, 2001 |
| Primary completion | Jan 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: